SLX1A-SULT1A3: A Potential Drug Target and Biomarker (G100526830)

Target Name: SLX1A-SULT1A3

NCBI ID: G100526830

SLX1A-SULT1A3

SLX1A-SULT1A3: A Potential Drug Target and Biomarker

SLX1A-SULT1A3 is a protein that is expressed in various tissues of the body, including the brain, pancreas, and liver. Its full name is sulfate protease 1A3, and it is a member of the proteasome family 18. This protein plays a crucial role in the breaking down of sulfate-containing peptides, which are involved in various cellular processes.

SLX1A-SULT1A3 has been identified as a potential drug target due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases has led to the development of new therapeutic strategies, including targeted therapies and combination therapies.

One of the key advantages of SLX1A-SULT1A3 as a drug target is its high expression level in various tissues, which makes it an attractive target for small molecules. Additionally, its role in the proteasome system makes it a potential candidate for inhibitors that can be used to treat protein-related diseases.

SLX1A-SULT1A3 has also been identified as a biomarker for several diseases, including neurodegenerative diseases and cancer. Its expression has been shown to be elevated in individuals with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and has also been associated with increased risk of cancer.

In addition to its potential as a drug target and biomarker, SLX1A-SULT1A3 has also been shown to play a role in various cellular processes that are important for its function. For example, SLX1A-SULT1A3 has been shown to be involved in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in various cellular processes, including cell growth, differentiation, and inflammation.

SLX1A-SULT1A3 has also been shown to play a role in the regulation of protein synthesis and degradation. Its expression has been shown to be involved in the translation of mRNAs to the ribosome, as well as in the degradation of damaged proteins.

In conclusion, SLX1A-SULT1A3 is a protein that has the potential to be a drug target and biomarker for a variety of diseases. Its high expression level in various tissues and its involvement in various cellular processes make it an attractive target for small molecules and other therapeutic strategies. Further research is needed to fully understand its role in these diseases and to develop effective treatments.

Protein Name: SLX1A-SULT1A3 Readthrough (NMD Candidate)

The "SLX1A-SULT1A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLX1A-SULT1A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets